Apnea can be defined as cessation of respiratory effort lasting more than 20 seconds, or if shorter duration, accompanied with bradycardia or cyanosis. Apneic episodes are more common in infants and premature babies, but they can occur at any age. Although there is considerable overlap between causes of apnea in infants and children, the etiology among older children is similar to that of adults. Apnea can be a manifestation of a variety of serious conditions, and at the outset should be differentiated from benign causes such as breath-holding spells and snoring. Apnea could be central (depressed respiratory center with no efferent output), obstructive (obstruction to airflow causing inadequate ventilation) or mixed (both central and obstructive).
While the most frequent cause of apnea in infants is idiopathic, obstructive sleep apnea due to tonsil/adenoidal hypertrophy, often coexisting with obesity, is the most common cause in children. Other conditions that predispose individuals to obstructive sleep apnea (OSA) include:
Sickle cell anemia has been associated with OSA, but its mechanism is unclear. Predominant central causes of apnea include central nervous system (CNS) infections, raised intracranial pressure (accidental or inflicted head trauma, hydrocephalus, tumors), toxin exposures (CNS depressants, carbon monoxide poisoning), and central idiopathic hypoventilation. Neuromuscular disorders (Guillain-Barré syndrome, Duchenne muscular dystrophy, Werdnig-Hoffman disease) often cause mixed apnea. Morbid obesity itself can cause hypoventilation (Pickwickian syndrome) and predispose to apnea. Laryngospasm can occur as a protective reflex during episodes of gastroesophageal reflux and should be suspected when episodes are associated with feeding.
There are no good epidemiological studies related to apnea in children and very few studies related to OSA. The prevalence of OSA among otherwise healthy children is estimated to be 1% to 3%, and obesity is thought to increase this risk by four to five times. OSA is more common among black (3.5 times higher) and Hispanic children than white children. Most children with obstructive sleep apnea are aged between 2 to 10 years and usually present around four years of age.
Central apnea is a result of direct depression of the respiratory center affecting its efferent outputs that stimulate breathing. Neuromuscular disorders cause both central and obstructive apnea (impaired pharyngeal tone and paralysis of the respiratory muscles).
The pathophysiology of obstructive sleep apnea is not as clear. Professionals speculate that airway obstruction triggers electrocortical arousal which activates the autonomic nervous system that stimulates increased respiratory effort and tachypnea. There may also be subtle alterations to the central chemosensitive arousal network, particularly to hypercapnia in addition to diminished laryngeal reflexes to mechanoreceptor and chemoreceptor stimulation. These blunted responses are thought to play a role in obstructive sleep apnea. Furthermore, children develop oxygen desaturation much earlier than adults due to their higher respiratory rates for a similar degree of obstruction. Most children with obstructive sleep apnea have impaired arousal responses to inspiratory stimuli during rapid eye movement (REM) and non-REM sleep. The key element of obstructed sleep apnea is disordered breathing in sleep that manifests as both apnea and hypopnea.
A detailed history characterizing the event in terms of duration and associated symptoms, including a change in color and mental status, relationship to sleep, and feeding should be obtained. History with a particular focus on prematurity, known congenital, metabolic or genetic disorders, neurological conditions and previous similar episodes should be obtained. Any possibility of exposure to toxic substances should be ascertained. A family history of snoring, exposure to tobacco smoke, and nasal allergies are all strongly associated with obstructive sleep apnea. History of fever, cough, and rhinorrhea suggests an infectious cause and chronic mouth breathing and snoring. Excessive daytime sleeping suggests upper airway obstruction. Other symptoms of OSA include restlessness, frequent nightmares, difficulty to wake up, enuresis, other behavior problems, and overall irregular sleep patterns.
Abnormal vital signs should be addressed emergently, but in most cases, the child appears well at the time of evaluation. Abnormal size and appearance of the child may offer clues towards identifying an underlying metabolic or genetic abnormality, and unexplained skin bruises may suggest child abuse. Cyanosis represents poor perfusion or hypoxia, and pallor is suggestive of anemia.
Altered mental status, bulging fontanelles indicate increased intracranial pressure and presence of fever and rhinorrhea suggests upper airway infection or bronchiolitis. Sonorous breathing indicates obstruction at the pharyngeal level (tonsil/adenoidal hypertrophy), stridor suggests upper airway obstruction and wheeze lower airway obstruction (asthma). Characteristic adenoid facies (underdeveloped thin nostrils, short upper lip, prominent upper teeth, crowded teeth, narrow upper alveolus, high-arched palate, hypoplastic maxilla) with mouth breathing, nasal speech, and periorbital swelling may be present in 15% to 20% of children with OSA.
The performance of lab and imaging studies should be based on indications uncovered by the history and physical examination. If OSA is suspected, polysomnography is considered to be the gold standard for diagnosis and determination of severity. Lateral neck x-rays may show adenoidal hypertrophy or other abnormalities, but these are not diagnostic. Pulse oximetry when asleep and/or sleep questionnaires may be used to identify children when polysomnography is not feasible.
The management of apnea in infants is geared toward identifying the underlying cause, and therapeutic interventions are directed toward the identified condition. For OSA, the first-line treatment is adenotonsillectomy, with other options being tonsillotomy, tongue reduction surgeries, and tracheostomy in selected patients. While continuous positive airway pressure (CPAP) is the mainstay of therapy for most adults, though effective for moderate OSA, these devices are hard to use in children as they are not well tolerated.
Overall medical therapy has limited value in OSA. Fluticasone administered nasally for six weeks reduced the frequency of obstructive events in children, but the effect is not long lasting, and it was used in mild OSA. Systemic steroids have no role in treating OSA. In a double-blind, randomized control trial, oral montelukast for six weeks decreased the severity of OSA and adenoidal hypertrophy. Consultation with specialists should be based on the identified cause of apnea.
Long-term consequences of untreated OSA include neurocognitive disabilities, behavior problems, growth failure, pectus excavatum, scoliosis, pulmonary hypertension, and cor-pulmonale.
A polysomnographic-derived index known as the apnea-hypopnea index (apnea-hypopnea index equals the total number of apneas and hypopneas/total duration of sleep in hours) can be used to determine severity. An apnea-hypopnea index of less than one is considered to be normal in children. An apnea-hypopnea index of more than 20 is considered severely abnormal.